Ali A. Alkhabbaz

Ali A. Alkhabbaz

Auto-generated profile, based on publicly available information

Ali A. Alkhabbaz

Mohamad Al Dakhan Eye Center, Ministry of Health, Kuwait City, Kuwait

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2023 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
MEMohammad Ebrahim
Mohammad Ebrahim
AAAli A. Alkhabbaz
Ali A. Alkhabbaz
BAButhaina Albash
Buthaina Albash
AAAli H. AlSayegh
Ali H. AlSayegh
GWGregory Webster
Gregory Webster

28 November 2024 in American Journal of Ophthalmology
Verified
Journal Article
Closed access
AAAli A. Alkhabbaz
Ali A. Alkhabbaz
MKMohammad H Karam
Mohammad H Karam
APAndré S. Pollmann
André S. Pollmann
SNSiddharth Nath
Siddharth Nath
TLTsz Hin Alexander Lau
Tsz Hin Alexander Lau
SJSamir Jabbour
Samir Jabbour

5 April 2025 in Canadian Journal of Ophthalmology
Verified
Journal Article
Open access
AAAli Alkhabbaz
Ali Alkhabbaz
MKMohammad Karam
Mohammad Karam
MGMarwa Al Ghafri
Marwa Al Ghafri
ASAdam Samet
Adam Samet
BABryan Arthurs
Bryan Arthurs
CEChristian El-Hadad
Christian El-Hadad
To compare the efficacy of levobupivacaine versus bupivacaine for peribulbar block in ophthalmic surgery. A systematic review and meta-analysis were performed as per the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Publications in MEDLINE, EMBASE, EMCARE, CINAHL, and the Cochrane Central Register of Controlled Trials (CENTRAL) that compared levobupivacaine and bupivacaine for peribulbar block in ophthalmic surgery were screened for eligibility from inception through December 22, 2023. Our analyses were summarized by calculating mean differences (MD) for continuous variables and odds ratios (OR) for dichotomous variables, using either fixed-effects or random-effects meta-analysis based on the level of heterogeneity. Eight randomized control trials enrolling 800 patients were identified in the English literature published between 1998 and 2023. There was no statistically significant difference in akinesia score at 2 minutes (MD = 0.17; p = 0.12) or 10 minutes postinjection (MD = 0.02; p = 0.89). Similarly, there was no statistically significant difference between the 2 groups in terms of time of onset of the anesthetic effect (MD = 0.38; p = 0.36), postoperative diplopia (OR = 0.62; p = 0.17), incidence of systemic hypotension (OR = 1.00; p = 1.00) or verbal pain scales during the block (MD = 0.04; p = 0.66), at the end of surgery (MD = -0.01; p = 0.94) or 4 hours postoperatively (MD = -0.00; p = 0.98). As a result of conducting this meta-analysis, we conclude that there is no significant difference between levobupivacaine and bupivacaine in terms of akinesia score, time to onset of anesthetic effect, verbal pain scales, postoperative diplopia, or incidence of systemic hypotension.

2 April 2025 in Journal of American Association for Pediatric Ophthalmology and Strabismus
Verified
Journal Article
Open access
AAAli A. Alkhabbaz
Ali A. Alkhabbaz
MBMoath O. Baeshen
Moath O. Baeshen
STStuti M. Tanya
Stuti M. Tanya
DTDaniela Toffoli
Daniela Toffoli
Lamb-Shaffer syndrome is a rare neuro-developmental disorder associated with haploinsufficiency of the SOX5 gene. Clinical manifestations include speech delay, behavioral challenges, intellectual disability, and dysmorphic features. Up to 57% of patients have ophthalmic findings, including strabismus, refractive error, and optic nerve abnormalities. We present 2 siblings who are the first documented cases of Lamb-Shaffer syndrome with the p.R571W: c.1711 C>T SOX5 mutation to demonstrate optic nerve atrophy.